Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
The global Conjugate Vaccines market is projected to grow from US$ 10420 million in 2023 to US$ 12920 million by 2029, at a Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period.
麻豆原创 competition is intense. Pfizer, GSK, Sanofi, Merck, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 86.11% market share in 2019.
Report Includes:
This report presents an overview of global market for Conjugate Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Conjugate Vaccines, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Conjugate Vaccines, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Conjugate Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Conjugate Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Conjugate Vaccines sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Neuron Biotech, Serum Institute of India, Pfizer, Sanofi Pasteur, Bharat Biotech, Biological, GlaxoSmithKline and Merck, etc.
By Company
Novartis
Neuron Biotech
Serum Institute of India
Pfizer
Sanofi Pasteur
Bharat Biotech
Biological
GlaxoSmithKline
Merck
CSL
Segment by Type
Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccines
Segment by Application
Children
Adults
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Conjugate Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Conjugate Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Conjugate Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Conjugate Vaccines Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Conjugate Vaccines 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Monovalent Conjugate Vaccines
1.2.3 Multivalent Conjugate Vaccines
1.3 麻豆原创 by Application
1.3.1 Global Conjugate Vaccines 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Children
1.3.3 Adults
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Conjugate Vaccines Sales Estimates and Forecasts 2018-2029
2.2 Global Conjugate Vaccines Revenue by Region
2.2.1 Global Conjugate Vaccines Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Conjugate Vaccines Revenue by Region (2018-2023)
2.2.3 Global Conjugate Vaccines Revenue by Region (2024-2029)
2.2.4 Global Conjugate Vaccines Revenue 麻豆原创 Share by Region (2018-2029)
2.3 Global Conjugate Vaccines Sales Estimates and Forecasts 2018-2029
2.4 Global Conjugate Vaccines Sales by Region
2.4.1 Global Conjugate Vaccines Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Conjugate Vaccines Sales by Region (2018-2023)
2.4.3 Global Conjugate Vaccines Sales by Region (2024-2029)
2.4.4 Global Conjugate Vaccines Sales 麻豆原创 Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Conjugate Vaccines Sales by Manufacturers
3.1.1 Global Conjugate Vaccines Sales by Manufacturers (2018-2023)
3.1.2 Global Conjugate Vaccines Sales 麻豆原创 Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Conjugate Vaccines in 2022
3.2 Global Conjugate Vaccines Revenue by Manufacturers
3.2.1 Global Conjugate Vaccines Revenue by Manufacturers (2018-2023)
3.2.2 Global Conjugate Vaccines Revenue 麻豆原创 Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Conjugate Vaccines Revenue in 2022
3.3 Global Key Players of Conjugate Vaccines, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Conjugate Vaccines Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Conjugate Vaccines 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Conjugate Vaccines, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Conjugate Vaccines, Product Offered and Application
3.8 Global Key Manufacturers of Conjugate Vaccines, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Conjugate Vaccines Sales by Type
4.1.1 Global Conjugate Vaccines Historical Sales by Type (2018-2023)
4.1.2 Global Conjugate Vaccines Forecasted Sales by Type (2024-2029)
4.1.3 Global Conjugate Vaccines Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Conjugate Vaccines Revenue by Type
4.2.1 Global Conjugate Vaccines Historical Revenue by Type (2018-2023)
4.2.2 Global Conjugate Vaccines Forecasted Revenue by Type (2024-2029)
4.2.3 Global Conjugate Vaccines Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Conjugate Vaccines Price by Type
4.3.1 Global Conjugate Vaccines Price by Type (2018-2023)
4.3.2 Global Conjugate Vaccines Price Forecast by Type (2024-2029)
5 麻豆原创 Size by Application
5.1 Global Conjugate Vaccines Sales by Application
5.1.1 Global Conjugate Vaccines Historical Sales by Application (2018-2023)
5.1.2 Global Conjugate Vaccines Forecasted Sales by Application (2024-2029)
5.1.3 Global Conjugate Vaccines Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Conjugate Vaccines Revenue by Application
5.2.1 Global Conjugate Vaccines Historical Revenue by Application (2018-2023)
5.2.2 Global Conjugate Vaccines Forecasted Revenue by Application (2024-2029)
5.2.3 Global Conjugate Vaccines Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Conjugate Vaccines Price by Application
5.3.1 Global Conjugate Vaccines Price by Application (2018-2023)
5.3.2 Global Conjugate Vaccines Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Conjugate Vaccines 麻豆原创 Size by Type
6.1.1 US & Canada Conjugate Vaccines Sales by Type (2018-2029)
6.1.2 US & Canada Conjugate Vaccines Revenue by Type (2018-2029)
6.2 US & Canada Conjugate Vaccines 麻豆原创 Size by Application
6.2.1 US & Canada Conjugate Vaccines Sales by Application (2018-2029)
6.2.2 US & Canada Conjugate Vaccines Revenue by Application (2018-2029)
6.3 US & Canada Conjugate Vaccines 麻豆原创 Size by Country
6.3.1 US & Canada Conjugate Vaccines Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Conjugate Vaccines Sales by Country (2018-2029)
6.3.3 US & Canada Conjugate Vaccines Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Conjugate Vaccines 麻豆原创 Size by Type
7.1.1 Europe Conjugate Vaccines Sales by Type (2018-2029)
7.1.2 Europe Conjugate Vaccines Revenue by Type (2018-2029)
7.2 Europe Conjugate Vaccines 麻豆原创 Size by Application
7.2.1 Europe Conjugate Vaccines Sales by Application (2018-2029)
7.2.2 Europe Conjugate Vaccines Revenue by Application (2018-2029)
7.3 Europe Conjugate Vaccines 麻豆原创 Size by Country
7.3.1 Europe Conjugate Vaccines Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Conjugate Vaccines Sales by Country (2018-2029)
7.3.3 Europe Conjugate Vaccines Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Conjugate Vaccines 麻豆原创 Size
8.1.1 China Conjugate Vaccines Sales (2018-2029)
8.1.2 China Conjugate Vaccines Revenue (2018-2029)
8.2 China Conjugate Vaccines 麻豆原创 Size by Application
8.2.1 China Conjugate Vaccines Sales by Application (2018-2029)
8.2.2 China Conjugate Vaccines Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Conjugate Vaccines 麻豆原创 Size by Type
9.1.1 Asia Conjugate Vaccines Sales by Type (2018-2029)
9.1.2 Asia Conjugate Vaccines Revenue by Type (2018-2029)
9.2 Asia Conjugate Vaccines 麻豆原创 Size by Application
9.2.1 Asia Conjugate Vaccines Sales by Application (2018-2029)
9.2.2 Asia Conjugate Vaccines Revenue by Application (2018-2029)
9.3 Asia Conjugate Vaccines Sales by Region
9.3.1 Asia Conjugate Vaccines Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Conjugate Vaccines Revenue by Region (2018-2029)
9.3.3 Asia Conjugate Vaccines Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Conjugate Vaccines 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Conjugate Vaccines Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Conjugate Vaccines Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Conjugate Vaccines 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Conjugate Vaccines Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Conjugate Vaccines Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Conjugate Vaccines Sales by Country
10.3.1 Middle East, Africa and Latin America Conjugate Vaccines Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Conjugate Vaccines Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Conjugate Vaccines Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Overview
11.1.3 Novartis Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Novartis Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novartis Recent Developments
11.2 Neuron Biotech
11.2.1 Neuron Biotech Company Information
11.2.2 Neuron Biotech Overview
11.2.3 Neuron Biotech Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Neuron Biotech Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Neuron Biotech Recent Developments
11.3 Serum Institute of India
11.3.1 Serum Institute of India Company Information
11.3.2 Serum Institute of India Overview
11.3.3 Serum Institute of India Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Serum Institute of India Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Serum Institute of India Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Pfizer Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Sanofi Pasteur
11.5.1 Sanofi Pasteur Company Information
11.5.2 Sanofi Pasteur Overview
11.5.3 Sanofi Pasteur Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Sanofi Pasteur Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Sanofi Pasteur Recent Developments
11.6 Bharat Biotech
11.6.1 Bharat Biotech Company Information
11.6.2 Bharat Biotech Overview
11.6.3 Bharat Biotech Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Bharat Biotech Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Bharat Biotech Recent Developments
11.7 Biological
11.7.1 Biological Company Information
11.7.2 Biological Overview
11.7.3 Biological Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Biological Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Biological Recent Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Information
11.8.2 GlaxoSmithKline Overview
11.8.3 GlaxoSmithKline Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 GlaxoSmithKline Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 GlaxoSmithKline Recent Developments
11.9 Merck
11.9.1 Merck Company Information
11.9.2 Merck Overview
11.9.3 Merck Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Merck Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Merck Recent Developments
11.10 CSL
11.10.1 CSL Company Information
11.10.2 CSL Overview
11.10.3 CSL Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 CSL Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 CSL Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Conjugate Vaccines Industry Chain Analysis
12.2 Conjugate Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Conjugate Vaccines Production Mode & Process
12.4 Conjugate Vaccines Sales and 麻豆原创ing
12.4.1 Conjugate Vaccines Sales Channels
12.4.2 Conjugate Vaccines Distributors
12.5 Conjugate Vaccines Customers
13 麻豆原创 Dynamics
13.1 Conjugate Vaccines Industry Trends
13.2 Conjugate Vaccines 麻豆原创 Drivers
13.3 Conjugate Vaccines 麻豆原创 Challenges
13.4 Conjugate Vaccines 麻豆原创 Restraints
14 Key Findings in The Global Conjugate Vaccines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Novartis
Neuron Biotech
Serum Institute of India
Pfizer
Sanofi Pasteur
Bharat Biotech
Biological
GlaxoSmithKline
Merck
CSL
听
听
*If Applicable.
